Cancer Drug ‘Strategic Reserve’ May Be Shortage Solution, US FDA’s Pazdur Says
Executive Summary
A national stockpile could provide immediate relief in the case of shortages, but also a ‘floor’ under pricing that might prevent more shortages in the first place, the head of the US FDA’s Oncology Center of Excellence says.
You may also be interested in...
House Republicans: Drug Shortage Solutions Must Move Beyond FDA
Energy and Commerce Republicans held off Democrats’ efforts to add drug shortage legislation back into the subcommittee-cleared pandemic preparedness bill 13 July. FDA-focused solutions have failed, GOP members said.
US FDA’s Cancer Drug/Diagnostic Pilot Program Aims To Close The Gap Between Regulation And Clinical Practice
Laboratory-developed tests may be misidentifying patients for treatment with targeted therapies. Under a new initiative, the FDA will work with sponsors to develop minimum performance characteristics for LDTs that may be used with an approved cancer drug in clinical practice.
US FDA Finds Poor Data Integrity At Second Intas Plant
After machines counted particles in vials, workers revised reports so out-of-specification batches could be exported to the US and the EU.